|
CN1312135C
(zh)
*
|
1997-09-29 |
2007-04-25 |
明治制果株式会社 |
三环三唑并苯并氮杂䓬衍生物、用于制备该衍生物的方法和抗变态反应剂
|
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
|
US7919109B2
(en)
*
|
1999-02-08 |
2011-04-05 |
Intarcia Therapeutics, Inc. |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
|
|
CN1275968C
(zh)
*
|
2001-12-26 |
2006-09-20 |
明治制果株式会社 |
三环型三唑并苯并氮杂䓬衍生物的非晶态物质
|
|
WO2003066634A1
(en)
*
|
2002-02-07 |
2003-08-14 |
Neurogen Corporation |
Substituted fused pyrazolecarboxylic acid arylamides and related compounds
|
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
DE602005003951T4
(de)
|
2004-05-14 |
2012-10-11 |
Millennium Pharmaceuticals, Inc. |
Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
ATE481963T1
(de)
|
2006-05-30 |
2010-10-15 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
|
AU2007284759B2
(en)
|
2006-08-09 |
2010-10-28 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies
|
|
CL2007003244A1
(es)
|
2006-11-16 |
2008-04-04 |
Millennium Pharm Inc |
Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
|
|
MX2009011123A
(es)
|
2007-04-23 |
2009-11-02 |
Intarcia Therapeutics Inc |
Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
|
|
DK2240155T3
(da)
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
|
CN102264368B
(zh)
|
2008-12-22 |
2014-09-10 |
米伦纽姆医药公司 |
极光激酶抑制剂与抗cd20抗体的组合
|
|
JO3635B1
(ar)
|
2009-05-18 |
2020-08-27 |
Millennium Pharm Inc |
مركبات صيدلانية صلبة وطرق لانتاجها
|
|
KR102093612B1
(ko)
|
2009-09-28 |
2020-03-26 |
인타르시아 세라퓨틱스 인코포레이티드 |
실질 항정상태 약물 전달의 신속 확립 및/또는 종결
|
|
CN104031049A
(zh)
|
2010-02-19 |
2014-09-10 |
米伦纽姆医药公司 |
极光激酶抑制剂的结晶形式
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
US20130303519A1
(en)
|
2012-03-20 |
2013-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treating cancer using aurora kinase inhibitors
|
|
US9724354B2
(en)
|
2013-03-22 |
2017-08-08 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
KR102650751B1
(ko)
|
2015-06-03 |
2024-03-22 |
인타르시아 세라퓨틱스 인코포레이티드 |
임플란트 배치 및 제거 시스템들
|
|
JP2018524292A
(ja)
|
2015-07-21 |
2018-08-30 |
ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
オーロラキナーゼインヒビターと化学療法剤の投与
|
|
CA3024479A1
(en)
|
2016-05-16 |
2017-11-23 |
Intarcia Therapeutics, Inc. |
Glucagon-receptor selective polypeptides and methods of use thereof
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
MX2019008006A
(es)
|
2017-01-03 |
2019-08-29 |
Intarcia Therapeutics Inc |
Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
|